Michela Cini
Research Subjects
Michela Cini has a total of 175 co-authors. Here are the top co-authors by number of shared publications:
- Cristina Legnani
Fondazione Arianna Anticoagulazione, Bologna, Italy
43 shared publications Gualtiero Palareti
Arianna Anticoagulazione Foundation Bologna Italy
22 shared publicationsBenilde Cosmi
Department of Angiology and Blood Coagulation S. Orsola‐Malpighi University Hospital Bologna Italy
17 shared publications- Michelangelo Sartori
Angiology and Blood Coagulation Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
10 shared publications Elisabetta Favaretto
Angiology and Blood Coagulation Unit, Department of Cardiothoracic and Vascular Diseases, IRCCS Azienda Ospedaliero-Universitaria Bologna, Italy
9 shared publications- Gualtiero Palareti
Arianna Anticoagulation Foundation, Bologna, Italy
9 shared publications
Latest Publications
- Open Access
- 22 October 2026
- Published by Hogrefe Publishing Group in Vasa
The START-SIAPAV-PAD Registry – Rationale, study design, and baseline characteristics of an ongoing Italian multicentre registry
Summary: Background: Peripheral artery disease (PAD) is associated with a high burden of cardiovascular and limb events, yet guideline-directed medical therapy remains suboptimal. The START-SIAPAV-PAD registry was designed to describe characteristics, management and clinical history of patients with PAD in Italy. Baseline characteristics and treatment are reported. Patients and methods: START-SIAPAV-PAD is a prospective, multicentre, observational registry enrolling consecutive adults with PAD managed at 20 Italian Vascular centres, starting in February 2023. Standardised electronic case-report forms collect demographics, risk factors, comorbidities, haemodynamic parameters, vascular anatomy, therapies. Follow-up is planned for a minimum of 3 years. PAD severity is classified according to the Leriche-Fontaine scale, and risk-factor targets follow the 2024 ESC guidelines. Results: The present analysis includes 517 patients (72.0% male; median age 71 years) with a high prevalence of hypertension (79.2%), dyslipidaemia (85.0%), diabetes (36.9%), smoking (96.1% current or former) and chronic kidney disease (21.2%). Nearly half reported a walking distance <200 m, 77.5% had a resting ankle–brachial index ≤.80, and 17.2% presented with Leriche-Fontaine stage IV. Femoropopliteal disease was most frequent (69.8%), with multilevel involvement in 43.4%. Previous revascularisation was common, major amputation was rare. LDL cholesterol target (<55mg dL) was achieved in 27.9% of patients despite lipid-lowering therapy in 82.1%. Dual pathway inhibition, advanced lipid-lowering therapies, supervised exercise and structured smoking-cessation programmes were insufficiently adopted. Conclusions: In a population with advanced PAD and multiple risk factors we observed a substantial gap between guideline recommendations and real-world practice. Longitudinal follow-up will assess outcomes and opportunities to improve PAD management.
- 22 October 2026
- Published by Hogrefe Publishing Group in Vasa
Open AccessThe START-SIAPAV-PAD Registry – Rationale, study design, and baseline characteristics of an ongoing Italian multicentre registry
Summary: Background: Peripheral artery disease (PAD) is associated with a high burden of cardiovascular and limb events, yet guideline-directed medical therapy remains suboptimal. The START-SIAPAV-PAD registry was designed to describe characteristics, management and clinical history of patients with PAD in Italy. Baseline characteristics and treatment are reported. Patients and methods: START-SIAPAV-PAD is a prospective, multicentre, observational registry enrolling consecutive adults with PAD managed at 20 Italian Vascular centres, starting in February 2023. Standardised electronic case-report forms collect demographics, risk factors, comorbidities, haemodynamic parameters, vascular anatomy, therapies. Follow-up is planned for a minimum of 3 years. PAD severity is classified according to the Leriche-Fontaine scale, and risk-factor targets follow the 2024 ESC guidelines. Results: The present analysis includes 517 patients (72.0% male; median age 71 years) with a high prevalence of hypertension (79.2%), dyslipidaemia (85.0%), diabetes (36.9%), smoking (96.1% current or former) and chronic kidney disease (21.2%). Nearly half reported a walking distance <200 m, 77.5% had a resting ankle–brachial index ≤.80, and 17.2% presented with Leriche-Fontaine stage IV. Femoropopliteal disease was most frequent (69.8%), with multilevel involvement in 43.4%. Previous revascularisation was common, major amputation was rare. LDL cholesterol target (<55mg dL) was achieved in 27.9% of patients despite lipid-lowering therapy in 82.1%. Dual pathway inhibition, advanced lipid-lowering therapies, supervised exercise and structured smoking-cessation programmes were insufficiently adopted. Conclusions: In a population with advanced PAD and multiple risk factors we observed a substantial gap between guideline recommendations and real-world practice. Longitudinal follow-up will assess outcomes and opportunities to improve PAD management.
- Open Access
- 16 September 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (18) , 4913-4923
More early bleeds associated with high baseline direct oral anticoagulant levels in atrial fibrillation: the MAS study
Treatment with direct oral anticoagulants (DOACs) in patients with atrial fibrillation (AF) is effective and safe. However, bleeding complications still occur. Whether DOAC level measurement may further improve treatment efficacy and safety is still an open issue. In the "Measure and See" study, venous blood was collected 15-30 days after DOAC initiation in patients with AF who were then followed up for 1 year to record the occurrence of major and clinically relevant nonmajor bleeding. DOAC plasma levels were measured in 1 laboratory, and results were kept blind to patients and treating doctors. Trough DOAC levels were assessed in 1657 patients (957 [57.7%] and 700 patients treated with standard and low-dose, respectively). Fifty bleeding events were recorded during 1606 years of follow-up (3.11% pt/yrs). Fifteen bleeding events (4.97% pt/yrs) occurred in patients with C-trough standardized values in the highest activity class (>0.50), whereas 35 events (2.69% pt/yrs) occurred in those with values in the 2 lower classes (≤0.50, P = .0401). Increasing DOAC levels and low-dose DOAC use were associated with increased bleeding risk in the first 3 months of treatment. Overall, 19% of patients receiving low doses had standardized values in the highest class. More bleeding occurred in patients on low (4.3% pt/yrs) vs standard (2.2% pt/yrs; P = .0160) dose DOAC. Early measurement of DOAC levels in patients with AF identified many individuals with high levels despite the low doses use and had more bleeding risk during the first 3 months of treatment. This trial was registered at www.ClinicalTrials.gov as #NCT03803579.
- 16 September 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (18) , 4913-4923
Open AccessMore early bleeds associated with high baseline direct oral anticoagulant levels in atrial fibrillation: the MAS study
Treatment with direct oral anticoagulants (DOACs) in patients with atrial fibrillation (AF) is effective and safe. However, bleeding complications still occur. Whether DOAC level measurement may further improve treatment efficacy and safety is still an open issue. In the "Measure and See" study, venous blood was collected 15-30 days after DOAC initiation in patients with AF who were then followed up for 1 year to record the occurrence of major and clinically relevant nonmajor bleeding. DOAC plasma levels were measured in 1 laboratory, and results were kept blind to patients and treating doctors. Trough DOAC levels were assessed in 1657 patients (957 [57.7%] and 700 patients treated with standard and low-dose, respectively). Fifty bleeding events were recorded during 1606 years of follow-up (3.11% pt/yrs). Fifteen bleeding events (4.97% pt/yrs) occurred in patients with C-trough standardized values in the highest activity class (>0.50), whereas 35 events (2.69% pt/yrs) occurred in those with values in the 2 lower classes (≤0.50, P = .0401). Increasing DOAC levels and low-dose DOAC use were associated with increased bleeding risk in the first 3 months of treatment. Overall, 19% of patients receiving low doses had standardized values in the highest class. More bleeding occurred in patients on low (4.3% pt/yrs) vs standard (2.2% pt/yrs; P = .0160) dose DOAC. Early measurement of DOAC levels in patients with AF identified many individuals with high levels despite the low doses use and had more bleeding risk during the first 3 months of treatment. This trial was registered at www.ClinicalTrials.gov as #NCT03803579.
- Open Access
- 10 April 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (8) , 1846-1856
Thrombotic events associated with low baseline direct oral anticoagulant levels in atrial fibrillation: the MAS study
Although effective and safe, treatment with direct oral anticoagulants (DOAC) in atrial fibrillation (AF) is still associated with thrombotic complications. Whether the measurement of DOAC levels may improve treatment efficacy is an open issue. We carried out the observational, prospective, multicenter Measure and See (MAS) study. Blood was collected 15 to 30 days after starting DOAC treatment in patients with AF who were followed-up for 1 year. Plasma samples were centralized for DOAC level measurement. Patients’ DOAC levels were converted into drug/dosage standardized values to allow a pooled analysis in a time-dependent, competitive-risk model. The measured values were transformed into standardized values (representing the distance of each value from the overall mean) by subtracting the DOAC-specific mean value from the original values and dividing by the standard deviation. Trough and peak DOAC levels were assessed in 1657 and 1303 patients, respectively. In total, 21 thrombotic complications were recorded during 1606 years of follow-up (incidence of 1.31% of patients per year). Of 21 thrombotic events, 17 occurred in patients whose standardized activity levels were below the mean of each DOAC (0); the incidence was the highest (4.82% of patients per year) in patients whose standardized values were in the lowest class (−1.00 or less). Early measurement of DOAC levels in patients with AF allowed us to identify most of the patients who, having low baseline DOAC levels, subsequently developed thrombotic complications. Further studies are warranted to assess whether thrombotic complications may be reduced by measuring baseline DOAC levels and modifying treatment when indicated. This trial was registered at www.ClinicalTrials.gov as #NCT03803579.
- 10 April 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (8) , 1846-1856
Open AccessThrombotic events associated with low baseline direct oral anticoagulant levels in atrial fibrillation: the MAS study
Although effective and safe, treatment with direct oral anticoagulants (DOAC) in atrial fibrillation (AF) is still associated with thrombotic complications. Whether the measurement of DOAC levels may improve treatment efficacy is an open issue. We carried out the observational, prospective, multicenter Measure and See (MAS) study. Blood was collected 15 to 30 days after starting DOAC treatment in patients with AF who were followed-up for 1 year. Plasma samples were centralized for DOAC level measurement. Patients’ DOAC levels were converted into drug/dosage standardized values to allow a pooled analysis in a time-dependent, competitive-risk model. The measured values were transformed into standardized values (representing the distance of each value from the overall mean) by subtracting the DOAC-specific mean value from the original values and dividing by the standard deviation. Trough and peak DOAC levels were assessed in 1657 and 1303 patients, respectively. In total, 21 thrombotic complications were recorded during 1606 years of follow-up (incidence of 1.31% of patients per year). Of 21 thrombotic events, 17 occurred in patients whose standardized activity levels were below the mean of each DOAC (0); the incidence was the highest (4.82% of patients per year) in patients whose standardized values were in the lowest class (−1.00 or less). Early measurement of DOAC levels in patients with AF allowed us to identify most of the patients who, having low baseline DOAC levels, subsequently developed thrombotic complications. Further studies are warranted to assess whether thrombotic complications may be reduced by measuring baseline DOAC levels and modifying treatment when indicated. This trial was registered at www.ClinicalTrials.gov as #NCT03803579.
- Open Access
- 17 October 2022
- Published by PAGEPress Publications in Bleeding, Thrombosis and Vascular Biology
- Vol. 1 (3)
Evaluation of Coaguchek® Pro II coagulation testing device performance to assess direct oral anticoagulant action. The DOAC-CHECK study
Direct oral anticoagulants (DOAC) measurement is recommended in specific conditions. A point-of-care testing should be used in emergency to qualitatively rule out relevant DOAC concentrations. The DOAC-CHECK Study aims to evaluate whether the use of CoaguChek® Pro II (Roche Diagnostics International Ltd, Rotkreuz, Switzerland) coagulation testing device can provide reliable information in patients treated with DOAC. The study was carried out in two FCSA (Italian Federation of Thrombosis Centers) centers. We choose 3 different concentration thresholds for our analysis (30, 50 and 100 ng/mL) and by ROC curves the ideal cut-off point was selected to be the one that yielded a sensitivity of at least 95% associated with the highest possible specificity. 512 patients were enrolled. For Edoxaban and Rivaroxaban, both CoaguChek® Pro II prothrombin time (PT) and activated partial thromboplastin time (aPTT) tests showed a sensitivity >95% corresponding to satisfying specificity values; negative predictive values resulted in the range 90-100%. At variance, CoaguChek® Pro II PT and aPTT tests did not seem to be useful for identifying Apixaban and Dabigatran concentrations higher than the pre-defined thresholds. Our results suggest that CoaguChek® Pro II coagulation testing device can be used to qualitatively identify relevant concentrations of Edoxaban or Rivaroxaban, but not of Apixaban or Dabigatran.
- 17 October 2022
- Published by PAGEPress Publications in Bleeding, Thrombosis and Vascular Biology
- Vol. 1 (3)
Open AccessEvaluation of Coaguchek® Pro II coagulation testing device performance to assess direct oral anticoagulant action. The DOAC-CHECK study
Direct oral anticoagulants (DOAC) measurement is recommended in specific conditions. A point-of-care testing should be used in emergency to qualitatively rule out relevant DOAC concentrations. The DOAC-CHECK Study aims to evaluate whether the use of CoaguChek® Pro II (Roche Diagnostics International Ltd, Rotkreuz, Switzerland) coagulation testing device can provide reliable information in patients treated with DOAC. The study was carried out in two FCSA (Italian Federation of Thrombosis Centers) centers. We choose 3 different concentration thresholds for our analysis (30, 50 and 100 ng/mL) and by ROC curves the ideal cut-off point was selected to be the one that yielded a sensitivity of at least 95% associated with the highest possible specificity. 512 patients were enrolled. For Edoxaban and Rivaroxaban, both CoaguChek® Pro II prothrombin time (PT) and activated partial thromboplastin time (aPTT) tests showed a sensitivity >95% corresponding to satisfying specificity values; negative predictive values resulted in the range 90-100%. At variance, CoaguChek® Pro II PT and aPTT tests did not seem to be useful for identifying Apixaban and Dabigatran concentrations higher than the pre-defined thresholds. Our results suggest that CoaguChek® Pro II coagulation testing device can be used to qualitatively identify relevant concentrations of Edoxaban or Rivaroxaban, but not of Apixaban or Dabigatran.
- Open Access
- 27 July 2021
- Published by Springer Nature in Internal and Emergency Medicine
- Vol. 17 (1) , 71-82
Unprovoked or provoked venous thromboembolism: not the prevalent criterion to decide on anticoagulation extension in clinical practice of various countries—the prospective, international, observational WHITE study
The decision on treatment after a first venous thromboembolism (VTE) to prevent recurrences may be influenced by many factors. The prospective, observational, WHITE study aimed to analyze how this issue was tackled in every-day clinical practice in various countries, which have sensibly different socio-economic conditions and healthcare systems. Doctors active in 79 Internal or Vascular clinical centers in 7 countries (China, Czechia, Poland, Portugal, Russia, Slovakia, and Tunisia) enrolled VTE patients after the maintenance treatment phase. The present report analyzed information, collected in the central database, regarding the baseline characteristics, index events, type and duration of anticoagulant therapy and decision on post-maintenance treatment. From April 2018 to December 2020, 1240 patients were enrolled, 58% with an unprovoked index event. Direct oral anticoagulants (DOACs) were used in > 85% of all cases in China, Poland, Portugal, Russia and Czechia, in 52% in Slovakia and in no patient in Tunisia. The maintenance anticoagulation lasted in average approximately 6 months. Altogether, anticoagulation was stopped in 20%, extended in about 50%, regardless of whether the event was unprovoked or provoked and shifted to antithrombotics (mainly sulodexide or aspirin) in the remaining patients. In conclusion, some differences in VTE patient management were found between countries. The provoked/unprovoked nature of the index event, instead, was not the prevalent criterion to drive the decision on extension of anticoagulation, without large variations between countries. DOACs were the most widely used anticoagulant drugs, whereas > 25% of patients received antithrombotic drugs instead of anticoagulants as extended treatment.
- 27 July 2021
- Published by Springer Nature in Internal and Emergency Medicine
- Vol. 17 (1) , 71-82
Open AccessUnprovoked or provoked venous thromboembolism: not the prevalent criterion to decide on anticoagulation extension in clinical practice of various countries—the prospective, international, observational WHITE study
The decision on treatment after a first venous thromboembolism (VTE) to prevent recurrences may be influenced by many factors. The prospective, observational, WHITE study aimed to analyze how this issue was tackled in every-day clinical practice in various countries, which have sensibly different socio-economic conditions and healthcare systems. Doctors active in 79 Internal or Vascular clinical centers in 7 countries (China, Czechia, Poland, Portugal, Russia, Slovakia, and Tunisia) enrolled VTE patients after the maintenance treatment phase. The present report analyzed information, collected in the central database, regarding the baseline characteristics, index events, type and duration of anticoagulant therapy and decision on post-maintenance treatment. From April 2018 to December 2020, 1240 patients were enrolled, 58% with an unprovoked index event. Direct oral anticoagulants (DOACs) were used in > 85% of all cases in China, Poland, Portugal, Russia and Czechia, in 52% in Slovakia and in no patient in Tunisia. The maintenance anticoagulation lasted in average approximately 6 months. Altogether, anticoagulation was stopped in 20%, extended in about 50%, regardless of whether the event was unprovoked or provoked and shifted to antithrombotics (mainly sulodexide or aspirin) in the remaining patients. In conclusion, some differences in VTE patient management were found between countries. The provoked/unprovoked nature of the index event, instead, was not the prevalent criterion to drive the decision on extension of anticoagulation, without large variations between countries. DOACs were the most widely used anticoagulant drugs, whereas > 25% of patients received antithrombotic drugs instead of anticoagulants as extended treatment.
- Open Access
- 1 January 2021
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 27
Anticoagulation Duration After First Venous Thromboembolism: Real-Life Data From the International, Observational WHITE Study
International guidelines recommend at least three months anticoagulation in all patients after acute venous thromboembolism (VTE) and suggest those with unprovoked events be considered for indefinite anticoagulation if the risk of recurrence is high and the risk of bleeding during treatment non-high. Other authors have recently argued against using a dichotomy unprovoked/provoked events to decide on anticoagulation duration and suggest instead using overall risk factors present in each patient as the basis for deciding. This sub-analysis of the WHITE study aimed at assessing the reasons for the treatment decisions taken by doctors in different countries. 1240 patients were recruited in 7 countries (China, Czechia, Poland, Portugal, Russia, Slovakia, and Tunisia). Anticoagulation was extended in 51.7% and 49.3% of patients with unprovoked or provoked events (n.s.); stopped in 15.4% versus 28.9% (P < .0001), and changed to antithrombotic drugs (sulodexide or aspirin) in 32.9% versus 21.8% (P < .0001). In the 430 subjects with isolated distal deep vein thrombosis (IDDVT) anticoagulation was stopped in 34.4%, continued in 37.0% (mainly those with post-thrombotic syndrome [PTS]) and switched to antithrombotics in the balance. High risk of recurrence was the most prevalent reason (>83% of cases) given to continue anticoagulation, regardless of nature and site of the index events, followed by risk of bleeding and presence of PTS signs. On average, attending physicians estimated the risk of recurrence in real life conditions, and the consequent therapeutic decision, using all the information available, not limiting to the location or nature of the index event.
- 1 January 2021
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 27
Open AccessAnticoagulation Duration After First Venous Thromboembolism: Real-Life Data From the International, Observational WHITE Study
International guidelines recommend at least three months anticoagulation in all patients after acute venous thromboembolism (VTE) and suggest those with unprovoked events be considered for indefinite anticoagulation if the risk of recurrence is high and the risk of bleeding during treatment non-high. Other authors have recently argued against using a dichotomy unprovoked/provoked events to decide on anticoagulation duration and suggest instead using overall risk factors present in each patient as the basis for deciding. This sub-analysis of the WHITE study aimed at assessing the reasons for the treatment decisions taken by doctors in different countries. 1240 patients were recruited in 7 countries (China, Czechia, Poland, Portugal, Russia, Slovakia, and Tunisia). Anticoagulation was extended in 51.7% and 49.3% of patients with unprovoked or provoked events (n.s.); stopped in 15.4% versus 28.9% (P < .0001), and changed to antithrombotic drugs (sulodexide or aspirin) in 32.9% versus 21.8% (P < .0001). In the 430 subjects with isolated distal deep vein thrombosis (IDDVT) anticoagulation was stopped in 34.4%, continued in 37.0% (mainly those with post-thrombotic syndrome [PTS]) and switched to antithrombotics in the balance. High risk of recurrence was the most prevalent reason (>83% of cases) given to continue anticoagulation, regardless of nature and site of the index events, followed by risk of bleeding and presence of PTS signs. On average, attending physicians estimated the risk of recurrence in real life conditions, and the consequent therapeutic decision, using all the information available, not limiting to the location or nature of the index event.
- 10 February 2020
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 42 (2) , 214-222
DOAC plasma levels measured by chromogenic anti‐Xa assays and HPLC‐UV in apixaban‐ and rivaroxaban‐treated patients from the START‐Register
Introduction: To measure direct factor Xa inhibitor (apixaban, edoxaban, rivaroxaban) concentrations, dedicated chromogenic anti‐Xa assays are recommended as suitable methods to provide rapid drug quantification. Moreover, the high‐performance liquid chromatography with ultraviolet detection (HPLC‐UV) is reported as a reliable quantitative technique. We investigated seven anti‐Xa assays and an HPLC‐UV method for measurement of apixaban and rivaroxaban levels in patients enrolled in the START‐Register.Methods: A total of 127 apixaban and 124 rivaroxaban samples were tested by HPLC‐UV and the following anti‐Xa assays: Biophen DiXaI and Heparin LRT (Hyphen BioMed), Berichrom and Innovance Heparin (Siemens), STA‐Liquid Anti‐Xa (Stago Diagnostics), Technochrom anti‐Xa (Technoclone), and HemosIL Liquid Anti‐Xa (Werfen). Each method was performed in one of the participating laboratories: Bologna, Cremona, Florence, and Padua.Results: Our data confirmed the overestimation of apixaban and rivaroxaban levels by the antithrombin‐supplemented anti‐Xa method (Berichrom). Performances and reproducibility of the six anti‐Xa assays not supplemented with antithrombin and the HPLC‐UV method were good, with limits of quantification from 8‐39 ng/mL (apixaban) and 15‐33 ng/mL (rivaroxaban). The six chromogenic methods showed good concordances with the quantitative HPLC‐UV [bias: −26.9‐22.3 ng/mL (apixaban), −11.3‐18.7 ng/mL (rivaroxaban)]. Higher bias and wider range between limits of agreement were observed at higher concentrations [200 ng/mL: bias −42.2‐36.8 ng/mL (apixaban) and −20.1‐68.9 ng/mL (rivaroxaban)].Conclusion: Overall, the anti‐Xa assays not supplemented with antithrombin and the HPLC‐UV method proved to be suitable for apixaban and rivaroxaban quantification.
- 10 February 2020
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 42 (2) , 214-222
DOAC plasma levels measured by chromogenic anti‐Xa assays and HPLC‐UV in apixaban‐ and rivaroxaban‐treated patients from the START‐Register
Introduction: To measure direct factor Xa inhibitor (apixaban, edoxaban, rivaroxaban) concentrations, dedicated chromogenic anti‐Xa assays are recommended as suitable methods to provide rapid drug quantification. Moreover, the high‐performance liquid chromatography with ultraviolet detection (HPLC‐UV) is reported as a reliable quantitative technique. We investigated seven anti‐Xa assays and an HPLC‐UV method for measurement of apixaban and rivaroxaban levels in patients enrolled in the START‐Register.Methods: A total of 127 apixaban and 124 rivaroxaban samples were tested by HPLC‐UV and the following anti‐Xa assays: Biophen DiXaI and Heparin LRT (Hyphen BioMed), Berichrom and Innovance Heparin (Siemens), STA‐Liquid Anti‐Xa (Stago Diagnostics), Technochrom anti‐Xa (Technoclone), and HemosIL Liquid Anti‐Xa (Werfen). Each method was performed in one of the participating laboratories: Bologna, Cremona, Florence, and Padua.Results: Our data confirmed the overestimation of apixaban and rivaroxaban levels by the antithrombin‐supplemented anti‐Xa method (Berichrom). Performances and reproducibility of the six anti‐Xa assays not supplemented with antithrombin and the HPLC‐UV method were good, with limits of quantification from 8‐39 ng/mL (apixaban) and 15‐33 ng/mL (rivaroxaban). The six chromogenic methods showed good concordances with the quantitative HPLC‐UV [bias: −26.9‐22.3 ng/mL (apixaban), −11.3‐18.7 ng/mL (rivaroxaban)]. Higher bias and wider range between limits of agreement were observed at higher concentrations [200 ng/mL: bias −42.2‐36.8 ng/mL (apixaban) and −20.1‐68.9 ng/mL (rivaroxaban)].Conclusion: Overall, the anti‐Xa assays not supplemented with antithrombin and the HPLC‐UV method proved to be suitable for apixaban and rivaroxaban quantification.
- Open Access
- 30 January 2019
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 41 (3) , 309-315
An in vitro study to investigate the interference of enoxaparin on plasma levels of direct oral factor Xa inhibitors measured by chromogenic assays
Introduction: Co‐administration of enoxaparin and a direct oral factor Xa inhibitor (xabans: apixaban, edoxaban, rivaroxaban) could give rise to the problem of overlapping the anti‐Xa activity when measuring direct oral anticoagulant (DOAC) levels. We aimed to evaluate in vitro the degree of the interference of increasing enoxaparin concentrations on xaban plasma levels measured by different chromogenic anti‐Xa assays with drug‐specific calibrators and controls.Methods: Seven plasma samples were spiked with apixaban, edoxaban, or rivaroxaban at fixed concentration, and enoxaparin at increasing concentrations (0, 0.125, 0.250, 0.50, 1.0, 1.50, and 2.0 IU/mL). The evaluated chromogenic assays were as follows: Biophen DiXaI and Biophen Heparin LRT (Hyphen BioMed), Berichrom Heparin and Innovance Heparin (Siemens), STA‐Liquid Anti‐Xa (Stago Diagnostics), Technochrom anti‐Xa (Technoclone), and HemosIL Liquid Anti‐Xa (Werfen).Results: The presence of enoxaparin caused increased DOAC levels, with over‐estimation depending on the anti‐Xa assay and on the heparin concentration in the sample. The smallest over‐estimation was in the sample with enoxaparin 0.125 IU/mL and the greatest in the sample with enoxaparin 2.0 IU/mL (0%, 3.1%, and 7.4% vs 583.8%, 526.1%, and 415.2% for apixaban, edoxaban, and rivaroxaban, respectively). Biophen DiXaI showed lower interference compared to other methods (maximum over‐estimation in the presence of enoxaparin 2.0 IU/mL: 56.4% dosing rivaroxaban by Biophen DIXaI vs 583.8% dosing apixaban by Berichrom Heparin).Conclusion: The presence of enoxaparin interferes with xabans measurement by chromogenic anti‐Xa assays causing falsely elevated DOAC levels, the over‐estimation being dependent on the anti‐Xa assay and on the heparin concentration in the sample.
- 30 January 2019
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 41 (3) , 309-315
Open AccessAn in vitro study to investigate the interference of enoxaparin on plasma levels of direct oral factor Xa inhibitors measured by chromogenic assays
Introduction: Co‐administration of enoxaparin and a direct oral factor Xa inhibitor (xabans: apixaban, edoxaban, rivaroxaban) could give rise to the problem of overlapping the anti‐Xa activity when measuring direct oral anticoagulant (DOAC) levels. We aimed to evaluate in vitro the degree of the interference of increasing enoxaparin concentrations on xaban plasma levels measured by different chromogenic anti‐Xa assays with drug‐specific calibrators and controls.Methods: Seven plasma samples were spiked with apixaban, edoxaban, or rivaroxaban at fixed concentration, and enoxaparin at increasing concentrations (0, 0.125, 0.250, 0.50, 1.0, 1.50, and 2.0 IU/mL). The evaluated chromogenic assays were as follows: Biophen DiXaI and Biophen Heparin LRT (Hyphen BioMed), Berichrom Heparin and Innovance Heparin (Siemens), STA‐Liquid Anti‐Xa (Stago Diagnostics), Technochrom anti‐Xa (Technoclone), and HemosIL Liquid Anti‐Xa (Werfen).Results: The presence of enoxaparin caused increased DOAC levels, with over‐estimation depending on the anti‐Xa assay and on the heparin concentration in the sample. The smallest over‐estimation was in the sample with enoxaparin 0.125 IU/mL and the greatest in the sample with enoxaparin 2.0 IU/mL (0%, 3.1%, and 7.4% vs 583.8%, 526.1%, and 415.2% for apixaban, edoxaban, and rivaroxaban, respectively). Biophen DiXaI showed lower interference compared to other methods (maximum over‐estimation in the presence of enoxaparin 2.0 IU/mL: 56.4% dosing rivaroxaban by Biophen DIXaI vs 583.8% dosing apixaban by Berichrom Heparin).Conclusion: The presence of enoxaparin interferes with xabans measurement by chromogenic anti‐Xa assays causing falsely elevated DOAC levels, the over‐estimation being dependent on the anti‐Xa assay and on the heparin concentration in the sample.
- Open Access
- 3 January 2018
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 40 (2) , 229-236
Comparison of five specific assays for determination of dabigatran plasma concentrations in patients enrolled in the START‐Laboratory Register
Introduction: Several specific assays are commercially available to determine dabigatran anticoagulant activity. Aims of this multicenter and multiplatform study were to compare five methods for dabigatran measurement and investigate their performances in the low concentration range.Methods: Dabigatran levels were analyzed in 295 plasma samples from patients enrolled in the START‐Laboratory Register by the following methods using dedicated calibrators and controls: STA‐ECA II (Diagnostica Stago), standard and low range Hemoclot Thrombin Inhibitors (Hyphen BioMed), Direct Thrombin Inhibitor Assay (Instrumentation Laboratory), Direct Thrombin Inhibitor Assay (Siemens), Technoclot DTI (Technoclone).Results: Methods showed variable agreement with the Hemoclot Thrombin Inhibitors assay used as reference test, with modest under‐ or overestimations (Bland‐Altman bias from −17.3 to 4.0 ng/mL). Limits of detection and quantification varied depending on the assay (4‐52 and 7‐82 ng/mL, respectively). Between‐run precision and accuracy were good for all methods for both quality control levels. Assay's repeatability assessed at very low dabigatran concentrations (from 10 to 60 ng/mL) was also acceptable, variability generally increased at lower drug levels.Conclusion: The five dabigatran‐specific assays evaluated in this study provided reliable assessment of dabigatran plasma levels, although showing different performances.
- 3 January 2018
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 40 (2) , 229-236
Open AccessComparison of five specific assays for determination of dabigatran plasma concentrations in patients enrolled in the START‐Laboratory Register
Introduction: Several specific assays are commercially available to determine dabigatran anticoagulant activity. Aims of this multicenter and multiplatform study were to compare five methods for dabigatran measurement and investigate their performances in the low concentration range.Methods: Dabigatran levels were analyzed in 295 plasma samples from patients enrolled in the START‐Laboratory Register by the following methods using dedicated calibrators and controls: STA‐ECA II (Diagnostica Stago), standard and low range Hemoclot Thrombin Inhibitors (Hyphen BioMed), Direct Thrombin Inhibitor Assay (Instrumentation Laboratory), Direct Thrombin Inhibitor Assay (Siemens), Technoclot DTI (Technoclone).Results: Methods showed variable agreement with the Hemoclot Thrombin Inhibitors assay used as reference test, with modest under‐ or overestimations (Bland‐Altman bias from −17.3 to 4.0 ng/mL). Limits of detection and quantification varied depending on the assay (4‐52 and 7‐82 ng/mL, respectively). Between‐run precision and accuracy were good for all methods for both quality control levels. Assay's repeatability assessed at very low dabigatran concentrations (from 10 to 60 ng/mL) was also acceptable, variability generally increased at lower drug levels.Conclusion: The five dabigatran‐specific assays evaluated in this study provided reliable assessment of dabigatran plasma levels, although showing different performances.
- 1 September 2017
- Published by Elsevier in Thrombosis Research
- Vol. 157, 20-22
Endothelial activation in patients with superficial vein thrombosis (SVT) of the lower limbs
- 1 September 2017
- Published by Elsevier in Thrombosis Research
- Vol. 157, 20-22
Endothelial activation in patients with superficial vein thrombosis (SVT) of the lower limbs